DOE’s Actinium-225 Supply Review Concerns an Isotope Behind 53% of Its Recent Shipments

A supply decision with a large historical footprint

The Department of Energy is asking customers to identify unmet demand for a cancer-research isotope while it considers whether and when to scale back federal production. What’s the Scoop With Broach compared that September 29, 2026 request with the shipment appendix in a federal audit and found that the isotope, actinium-225, accounted for 53.2% of the program’s isotope shipments during fiscal years 2020 through 2025 when its two separately listed production routes are combined.

That concentration gives the current decision particular accountability significance. DOE’s National Isotope Development Center set October 15, 2026 as the deadline for customers with unmet needs to express firm purchasing interest for the January–December 2027 supply term. The request specifically concerns thorium-229-derived actinium-225. It says commercial production is expanding and DOE wants to distinguish needs already met by industry from gaps that still require federal supply.

The records do not announce a cut, name a final production quantity, or show that patients will lose treatment. The question is whether DOE can make a transparent transition decision informed by actual unmet needs after auditors identified weaknesses in its broader demand-planning process.

The appendix shows why shipment counts need careful interpretation

GAO’s June 23 report, publicly released July 23, lists 3,820 shipments of actinium-225 and another 275 of accelerator-produced actinium-225. Their sum is 4,095 out of 7,702 total isotope shipments, or 53.17%. The first line alone is 49.60%; the separately labeled accelerator line adds 3.57 percentage points. Combining them measures the historical footprint of the same isotope across the two listed routes, not the volume subject to the current thorium-derived request.

The same tables show a concentrated distribution network. Oak Ridge National Laboratory accounted for 5,982 of the 7,702 shipments, or 77.7%, across all isotopes. Those are dispatch counts, not isotope mass, radioactivity, revenue, treatment courses or shares of national supply. A shipment can carry a different quantity from another, and commercial suppliers also operate. We therefore do not equate DOE’s shipment share with the share of American patients dependent on it.

GAO describes actinium-225’s use in targeted alpha therapy, which delivers radiation to cancer cells. Its appendix cautions that shipment numbers do not necessarily measure an isotope’s importance. A rarely shipped isotope can still be vital. That limitation cuts both ways: the 53.2% figure identifies a major operational concentration without proving that DOE should maintain any particular production level.

The market-planning gap and the agency’s answer

The audit found detailed individual market assessments but no systematic mechanism for proactively assessing overall isotope demand and aligning actions. The National Isotope Development Center completed six full market assessments and nine shorter snapshots during fiscal years 2020–2025. Officials said a full assessment could take up to three months and 200 staff hours. Manual tracking of customer communications made an aggregate view harder to assemble.

DOE agreed with all four recommendations. Its response committed to several planning and risk-management actions by October 2027 and to establishing the statutory advisory committee by December 2026. These are different milestones: the 2027 customer-request deadline arrives before the audit response’s later management deadlines. That timing does not establish a violation of those promises; it shows a consequential supply decision being developed while broader improvements remain scheduled.

Later public records provide material counterevidence to any portrayal of an inactive program. A September 21 announcement offers radium-226 processing and purification assistance to support medical-isotope feedstock. A July 9 announcement describes restored domestic stable-isotope enrichment and a new Oak Ridge facility expected to begin phased operation in 2028. Those initiatives concern different materials and capabilities; they do not answer how much thorium-derived actinium-225 will be offered in 2027.

What the current public record can establish

We rechecked the GAO recommendation page on October 15; all four recommendations remained listed open. DOE’s current advisory-committee directory includes the isotope committee by name, so the audit’s historical finding that it had not yet been established cannot alone support a claim that no committee exists today. The directory we reviewed did not provide a linked roster or meeting record for this entry, and we do not infer operational status from that absence.

This is original public-record analysis by What’s the Scoop With Broach: we joined the full audit’s shipment appendix, production-route distinctions and management response with DOE’s dated 2027 request and subsequent supply announcements. No interviews, site visits or purchasing requests by Billy Roach are claimed. The distinctive finding is the scale and timing of the decision, not a claim that federal withdrawal has already occurred. The next decisive public evidence is the resulting production decision and its explanation of unmet demand, commercial capacity and transition safeguards.